GEM 92

a second generation mixed-backbone, orally administered antisense oligonucleotide directed against the gag gene in HIV-1 mRNA, as a potential treatment for HIV-1 infection and AIDS ; similar to GEM91

Also Known As:

GEM-92; GEM92

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - Oligodeoxyribonucleotides: 2217
        GEM 92: 1

Related Diseases

1.	Infections 08/01/1999 - "Hybridon is developing GEM-92, a second generation, orally administered antisense oligonucleotide directed against the gag gene in HIV-1 mRNA, as a potential treatment for HIV-1 infection and AIDS 11973841. "
2.	Acquired Immunodeficiency Syndrome (AIDS) 08/01/1999 - "Hybridon is developing GEM-92, a second generation, orally administered antisense oligonucleotide directed against the gag gene in HIV-1 mRNA, as a potential treatment for HIV-1 infection and AIDS 11973841. "

Related Drugs and Biologics

1.	Antisense Oligonucleotides
2.	Messenger RNA (mRNA)